Endoscopic full-thickness resection (eFTR) of colorectal lesions: results from the Dutch colorectal eFTR registry

Authors
Liselotte W. Zwager1, Barbara A. J. Bastiaansen1, Maxime E. S. Bronzwaer1, Bas W. van der Spek2, G. Dimitri N. Heine2, Krijn J. C. Haasnoot3, Hedwig van der Sluis4, Lars E. Perk5, Jurjen J. Boonstra6, Svend T. Riedijk7, Hugo J. Wolters6, Bas L. A. M. Weusten9, Lennard P. L. Gilissen10, W. Rogier ten Hove11, Wouter B. Nagengast12, Frank C. Bekkerings13, M. P. Schwartz14, Jochim S. Terhaar sive Droste15, Marije S. Vlug16, Martin H. M. G. Houben17, Francisco J. Rando Munoz18, Tom C. J. Seerden19, Hanneke Beaumont20, Rogier de Ridder21, Evelien Dekker1, Paul Fockens1, on behalf of the Dutch eFTR Group

Institutions
1 Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Amsterdam Gastroenterology & Metabolism, University of Amsterdam, Amsterdam, The Netherlands
2 Department of Gastroenterology and Hepatology, Noordwest Hospital Group, Alkmaar, The Netherlands
3 Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
4 Department of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands
5 Department of Gastroenterology and Hepatology, Haaglanden Medical Center, The Hague, The Netherlands
6 Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
7 Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
8 Department of Gastroenterology and Hepatology, Martini Hospital, Groningen, The Netherlands
9 Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands
10 Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands
11 Department of Gastroenterology and Hepatology, Afirjne Medical Group, Leiden, The Netherlands
12 Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands
13 Department of Gastroenterology and Hepatology, IJsselland Hospital, Capelle aan den IJssel, The Netherlands
14 Department of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, The Netherlands
15 Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch, The Netherlands
16 Department of Gastroenterology and Hepatology, Dijklander Hospital, Hoorn, The Netherlands
17 Department of Gastroenterology and Hepatology, Haga Teaching Hospital, The Hague, The Netherlands
18 Department of Gastroenterology and Hepatology, Nij Smeltinghe Hospital, Drachten, The Netherlands
19 Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, The Netherlands
20 Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, location VU, Amsterdam, The Netherlands
21 Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands

submitted 3.2.2020
accepted after revision 22.4.2020
published online 3.6.2020

Bibliography
Endoscopy 2020; 52: 1014–1023
DOI 10.1055/a-1176-1107
ISSN 0013-726X
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Corresponding author
Barbara Bastiaansen, MD, Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
b.a.bastiaansen@amsterdamumc.nl

Supplementary material
Online content viewable at: https://doi.org/10.1055/a-1176-1107

* Contributed equally to this article
Introduction

Endoscopic full-thickness resection (eFTR) is an emerging innovative endoscopic resection technique for complex colorectal lesions. With the advantage of enabling a transmural resection, eFTR offers an alternative to radical surgery in lesions considered incurable with current resection techniques such as endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD).

In clinical practice, the main indications for eFTR are non-lifting lesions with severe submucosal fibrosis, lesions that involve difficult anatomical locations such as the appendiceal orifice or diverticula, and subepithelial tumors. Furthermore, eFTR is gaining interest as a valid diagnostic and therapeutic treatment option for T1 colorectal cancer (CRC), as it can provide high quality pathological specimens and exact histological risk assessment [1].

Several studies have reported encouraging results on the short-term safety and efficacy of eFTR for numerous indications [1–12]. However, firm conclusions on clinical results will require analysis of large prospective series of patients in everyday clinical practice.

Since the introduction of the full-thickness resection device (FTRD; Ovesco Endoscopy AG, Tübingen, Germany) in the Netherlands in 2015, we started a nationwide prospective registry of all consecutive eFTR procedures to monitor patient outcomes and further increase knowledge on clinical applicability and safety. In this prospective observational multicenter study, we aimed to evaluate the technical and clinical success, and safety of eFTR for colorectal lesions in current clinical practice.

Methods

Study design

In this study, all registered procedures between July 2015 and October 2018 were analyzed. Results were prospectively recorded in 20 Dutch hospitals (5 academic and 15 non-academic). Procedures were performed by eFTR-certified gastroenterologists. For eFTR certification, experienced gastroenterologists attended a 1-day training course on eFTR, with thorough theoretical background and hands-on training in ex vivo porcine models.

Because the data were collected as part of standard medical care, the Institutional Review Board of the Amsterdam University Medical Centers decided that the study fell outside of the legislation regarding Medical Research Involving Human Subjects Act and therefore formal ethical approval was not deemed necessary. The study was registered in the Dutch Trial Register: NTR6292 (http://www.trialregister.nl/).

All patients were informed about the eFTR procedure and the peri-procedural risks by their treating physician and informed consent for the procedure was obtained. The results of 58 eFTR procedures were published previously [13, 14]. Coded data were collected into a secure online structured database provided by Castor EDC, Amsterdam, the Netherlands [15].

Outcome

The primary outcome was the technical success of all initiated procedures, defined as the proportion of macroscopic complete en bloc resections (judged by the endoscopist).

Secondary outcome measures included: clinical success, defined as the rate of histologically confirmed radical (R0) resections (tumor-free lateral and deep resection margins); rate of perforations; and adverse events (medical urgency or life-threatening).

Results

Between July 2015 and October 2018, 367 procedures were included. Indications were difficult polyps (non-lifting sign and/or difficult location; n = 133), primary resection of suspected T1 colorectal cancer (CRC; n = 71), re-resection after incomplete resection of T1 CRC (n = 150), and subepithelial tumors (n = 13). Technical success was achieved in 308 procedures (83.9%). In 21 procedures (5.7%), eFTR was not performed because the lesion could not be retracted or retracted into the cap. In the remaining 346 procedures, R0 resection was achieved in 285 (82.4%) and full-thickness resection in 288 (83.2%). The median diameter of resected specimens was 23 mm. Overall adverse event rate was 9.3% (n = 34/367): 10 patients (2.7%) required emergency surgery for five delayed and two immediate perforations and three cases of appendicitis.

Conclusion

eFTR is an effective and relatively safe en bloc resection technique for complex colorectal lesions with the potential to avoid surgery. Further studies assessing the role of eFTR in early CRC treatment with long-term outcomes are needed.
histologically confirmed full-thickness resection (presence of the muscularis propria in the resection specimen); procedure-related adverse events; and recurrence at first follow-up colonoscopy.

Study subjects
Eligibility for eFTR was judged by the treating physician after a complete colonoscopy had been performed. Indications for eFTR were “difficult polyps,” including non-lifting polyps (treatment naïve, recurrent, or incompletely resected polyps) and polyps involving the appendiceal orifice or a diverticulum; primary resection for suspected T1 CRCs; and secondary completion treatment after previous incomplete endoscopic resection with a positive (≤1 mm) or non-assessable resection margin (R1/Rx resection). Other indications for eFTR were subepithelial tumours. Because of the limited size of the FTRD cap, lesions with an estimated diameter of ≥30 mm were considered unsuitable for eFTR [16]. As this study used a prospective registry of current clinical practice, no explicit exclusion criteria were formulated.

eFTR procedure and management
All patients received standard split-dose polyethylene glycol (PEG) bowel preparation. Procedures were performed with the patient under sedation with propofol or midazolam and/or fentanyl, according to local practice. A single dose of prophylactic intravenous antibiotic therapy was advised for all eFTR procedures in the early study period, but since 2017 antibiotic prophylaxis was deemed unnecessary and was no longer advised, except for appendiceal lesions without previous appendectomy. Patients on anticoagulation therapy were advised to use their medication according to the Dutch guideline for antithrombotic therapy in endoscopy: coumarins and direct-acting oral anticoagulants (DOACs) were discontinued, single-agent antiplatelet agents could be continued [17]. The FTRD was used in all procedures, and these were performed using CO₂ insufflation.

First, the target lesion was identified during a diagnostic endoscopy and marked by creating coagulation marks with the dedicated probe or by other means, and the lesion size was estimated at the discretion of the endoscopist. Thereafter, the colonoscope was withdrawn, the FTRD was mounted and the colonoscope was advanced again to the target area. A specialized grasping forceps was advanced through the working channel to grasp and slowly pull the lesion into the cap. Once the lateral margins of the lesion were pulled into the cap, the clip was deployed. Immediately thereafter, the tissue was resected with the pre-loaded snare, while the clip secured the integrity of the bowel wall. The endoscope with the resection specimen entrapped in the cap was then withdrawn. After the specimen had been secured and the device demounted, the endoscope was introduced once again to inspect the position of the clip and the resection site. The specimen was stretched and pinned onto cork or paraffin before immersion into formalin for histological analysis (Fig. 1 and Fig. 2) [13]. To obtain the most...
accurate measurement of lesion and specimen size after eFTR, we used the size measured at histology.

Clinical admission for 24 hours to monitor signs of discomfort, bleeding, or perforation was advised in the early study period, but from 2017 the advice was withdrawn and this was left to the discretion of treating physician. The recommended dietary regimen was a clear fluid diet for 24 hours, followed by a normal diet.

Adverse events and follow-up

All immediate procedure-related adverse events that resulted in prolonged admission and/or an intervention (i.e. blood transfusion, re-colonoscopy, or surgery) were recorded at the time of colonoscopy. Delayed procedure-related adverse events requiring readmission or intervention (i.e. blood transfusion, colonoscopy, or surgery) were recorded approximately 14 days after eFTR, when patients were contacted to discuss the histopathological results. The severity of adverse events was graded according to the American Society for Gastrointestinal Endoscopy [18].

Patients were scheduled for follow-up colonoscopy after 3 – 6 months. The eFTR scar was inspected with high definition white-light endoscopy and (digital) chromoendoscopy for macroscopic recurrent or residual tissue and the presence of the clip. Endoscopic and/or histological findings compatible with granulation tissue or reactive changes were left untreated. Residual polyp tissue was treated with conventional treatment strategies if possible. When endoscopic resection of the residual polyp was considered impossible or submucosal invasive cancer was suspected, a tattoo (SPOT) was placed followed by case discussion in a colorectal multidisciplinary meeting. Follow-up colonoscopies were scheduled depending on histological and endoscopic findings. Patients referred for additional surgery after eFTR were excluded from scar surveillance.

Statistical analysis

Standard descriptive statistics were used. Variables are reported as mean with standard deviation (SD) for continuous and normally distributed variables, as median and interquartile range (IQR) for non-normally distributed continuous variables, and as percentages for counts or categorical variables. Categorical variables were analyzed using chi-squared or two-sided Fisher’s exact tests. A two-sided P value < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS 24 (SPSS, Chicago, Illinois, USA).

Results

Patients characteristics, procedural data, and technical success

A total of 367 eFTR procedures were performed in 362 patients between July 2015 and October 2018 and were included for analysis (63 % men; mean age 69 years). The indications were: difficult polyps (n = 133), primary resection of suspected T1 CRC (n = 71), re-resection after previous incomplete resection of T1 CRC (n = 150), and subepithelial tumors (n = 13). Proce-
dum procedures were performed by 37 certified endoscopists divided over 20 Dutch hospitals. Patient characteristics are shown in ▶ Table 1.

Technical success was achieved in 83.9 % of all procedures (n = 308/367) (▶ Table 2). In 1.9% of procedures (7/367), the target lesion could not be reached successfully (▶ Fig. 3). The main reason for not reaching the lesion was failure to pass the sigmoid colon with the FTRD in three procedures (42.9 %); for the other four procedures, no reason was described. In 14 procedures (3.9 %), the eFTR was not performed because the lesion could not be retracted into the cap owing to lack of mobility of the tissue. Of these 14 lesions, 12 were requiring re-resection after previous EMR.

In 346 procedures (94.3 %), it was possible to perform eFTR (lesion reached and clip deployed) and histology was obtained. Device malfunctions were reported in 32 of these 346 procedures (9.2 %). These were caused by snare malfunctions (n = 23; 6.6%), grasper dysfunction (n = 6; 1.7 %), and inability to release the clip (n = 3; 0.9%). However, it was possible to complete the resection in 22 of the snare malfunctions and five of the grasper dysfunctions.

Clinical success

In the total cohort of procedures amenable to eFTR (n = 346), histological R0 resection was achieved in 285 procedures (82.4 %) and full-thickness resection in 288 (83.2 %) (▶ Table 2). There were 14 cases that were judged during the procedure to be technically unsuccessful owing to macroscopic incomplete resection but were found to have tumor-free resection margins (R0) at histology (4.0 %). The median diameters of the resected lesions and the resected specimens at histology were 12 mm (IQR 8–17) and 23 mm (IQR 20–28), respectively. R0 resection for lesions > 20 mm was achieved in 72.7% vs. 78.3% for lesions ≤ 20 mm (P = 0.71).

eFTR in the subgroup of T1 CRCs (n = 221) was technical successful in 191 procedures (86.4 %) and R0 resection was achieved in 186 procedures (88.2 %). For primary resections of T1 CRCs, the R0 resection rate was 77.9% (n = 53) compared with 93.0% (n = 133) for secondary treatment (Table 1s).

After resection of the scar for previously incompletely resected T1 CRCs (R1/Rx), only scar tissue was found at histology in 117 procedures (81.8 %). Residual adenocarcinoma was found in 11 procedures (7.7 %). Of these, five patients were referred for additional oncological surgery because of high risk features for lymph node metastasis (LNMs) or an incomplete
eFTR. In one of these five patients, surgery was not performed owing to significant comorbidities. Of the four operated patients, one surgical specimen showed residual T2 cancer without LNM and one a T2 cancer with a positive lymph node. In the two other patients, no residual cancer was found.

In the subgroup of difficult polyps (n = 133), the procedure was technically successful in 105 procedures (70.5%). In the subepithelial lesions (n = 13), eFTR was technically successful in 12 cases (92.3%) and R0 resection was achieved in all cases (Table 2).

Adverse events
Overall, adverse events occurred in 34 procedures (9.3%) (Table 3). Severe adverse events occurred in 10 procedures (2.7%), including seven perforations (1.9%). In two patients, the perforation was noticed immediately; in both, the clip had not been released appropriately before the lesion was resected. In five patients delayed perforations occurred on days 1–8. In three of these, the lesion was located in the sigmoid and one of these patients was on immunosuppressive therapy for inflammatory bowel disease. The other two delayed perforations were located in the transverse colon and cecum. All seven patients needed surgical repair. In addition, three patients with an appendiceal lesion (n = 3/15; 20.0%) developed secondary appendicitis (all without previous appendectomy) and underwent an acute laparoscopic appendectomy (n = 2) or a laparoscopic ileocecal resection (n = 1).

| Table 2 | Technical success rates for all endoscopic full-thickness resection (eFTR) procedures initiated and clinical success rates in those amenable to EFTR. |
|---------|-----------------------------------|------------------|------------------|--------------------|
|         | Overall                          | T1 CRCs          | Difficult polyps | Subepithelial tumors |
| Initiated eFTR procedures, n | 367 | 221 | 133 | 13 |
| Technical success, n (%)   | 308 (83.9) | 191 (86.4) | 105 (78.9) | 12 (92.3) |
| Procedures amenable to eFTR, n† | 346 | 211 | 122 | 13 |
| Resection, n (%)            |       |       |       |       |
| ▪ R0                       | 285 (82.4) | 186 (88.2) | 86 (70.5) | 13 (100) |
| ▪ Full-thickness            | 288 (83.2) | 176 (83.4) | 100 (82.0) | 12 (92.3) |
| Lesion diameter, median (IQR), mm² |       |       |       |       |
| ▪ Lesion                    | 12 (8–17) | 13 (9–18) | 12 (8–15) | 9 (5–15) |
| ▪ Resected specimen         | 23 (20–28) | 23 (19–27) | 23 (20–29) | 26 (20–30) |
| Location lesion, n (%)      |       |       |       |       |
| ▪ Proximal                  | 131 (37.9) | 55 (26.1) | 76 (62.3) | 0 (0) |
| ▪ Distal                    | 215 (62.1) | 156 (73.9) | 46 (37.7) | 13 (100) |
| Histology, n (%)            |       |       |       |       |
| ▪ Normal colon tissue/scar  | 145 (41.9) | 120 (56.9) | 16 (13.1) | 8 (61.5) |
| ▪ Adenoma with LGD          | 75 (21.7) | 13 (6.2) | 63 (51.6) | 0 (0) |
| ▪ Adenoma with HGD          | 15 (4.3) | 5 (2.4) | 10 (8.2) | 0 (0) |
| ▪ Serrated polyp            | 17 (4.9) | 3 (1.4) | 14 (11.5) | 0 (0) |
| ▪ Adenocarcinoma            | 84 (24.3) | 67 (31.8) | 17 (13.9) | 0 (0) |
| ▪ Neuroendocrine tumor      | 5 (1.4) | 0 (0) | 0 (0) | 5 (38.5) |
| ▪ Other*                    | 3 (0.9) | 3 (1.4) | 0 (0) | 0 (0) |
| ▪ No pathology              | 2 (0.6) | 0 (0) | 2 (1.6) | 0 (0) |

CRC, colorectal cancer; IQR, interquartile range; LGD, low grade dysplasia; HGD, high grade dysplasia.
1 Ability to obtain histology (lesion was reached and over-the-scope clip deployed).
2 Size measured by the pathologist at histopathology.
3 Proximal is defined as cecum to splenic flexure and distal as descending colon to rectum.
4 The subgroup of T1 CRCs included a metastasis of gastric cancer (n = 1), signs of an inflammatory disease (n = 1), and the presence of mucin fields (n = 1).
Moderately severe adverse events were observed following eight procedures (2.2%). In seven (1.9%), post-procedural bleeding was observed that required re-admission or repeat endoscopy. In 16 (4.4%), a mild adverse event was observed. In two cases (0.5%), this was due to a perforation. The first perforation, which was seen immediately after the procedure, could be successfully clipped with an over-the-scope clip (OTSC). The second case, located in the sigmoid, occurred a few days after an uneventful eFTR and was treated conservatively with antibiotics and re-admission for 3 days. One patient with a history of appendectomy developed a peri-appendiceal abscess after eFTR for an appendiceal lesion and was treated conservatively.

**Surgery**

Overall, 65 patients (17.7%) underwent surgery after the initial eFTR procedure (Table 3). In 13 (3.5%), surgery was required because eFTR could not be performed (lesion not reached or clip not deployed); in 10 (2.7%), emergency surgery was performed because of an adverse event. Elective oncological surgery was performed in 29 patients (7.9%); in 11 (3.0%) after incomplete eFTR (R1/Rx), and in 18 (4.9%) because of high risk features for LNM. Of these elective surgery cases, histology was available in 26 (89.7%). Residual adenocarcinoma was found in three (11.5%) (Table 2s).

**Follow-up**

Endoscopic follow-up data were available for 187 procedures (63.4%) after eFTR and without additional surgery. Median time to follow-up was 4 months (IQR 3–6). In 31 procedures (16.6%), the clip was still in situ at follow-up. In 100 procedures (33.9%), endoscopic surveillance was still pending or not recorded. Furthermore, in the remaining eight cases (2.7%), no follow-up was scheduled. Reasons to refrain from follow-up were comorbidities (n = 3), no indication for follow-up (n = 2), or unclear reasons (n = 3). Residual/recurrent lesions were seen in 12 patients (6.4%). No adenocarcinomas were detected (Table 3s).

**Discussion**

In this study, we report the initial results of 367 eFTR procedures prospectively recorded in an eFTR registry in the Netherlands, representing the largest patient cohort published to date. While the interest and adoption of eFTR continues to grow amongst endoscopists, outcomes of large prospective series on its safety and efficacy are needed. In this multicenter collaboration, we aimed to investigate the clinical outcomes of eFTR for complex colorectal lesions.

In our study, the technical success rate for eFTR was 83.9% and R0 resection was achieved in 82.4% of the procedures. The results of our study are comparable with the results of the previous prospective study by Schmidt and colleagues, and to several other retrospective series [1–12]. In a meta-analysis comparing ESD and EMR for colorectal polyps, the R0 resection rate was 80.3% for ESD and 42.3% for EMR [19]. Therefore, R0 resection rates of eFTR are comparable with ESD and more favorable than EMR [20–25]. However, it is important to consider that this cohort mainly includes complex colorectal lesions, considered unsuitable for conventional endoscopic en bloc resection techniques. En bloc excision is always preferred as it provides a higher quality pathological specimen and lower recurrence rates. This advantage should however be balanced against a higher perforation risk [24]. eFTR can tackle the chal-

---

**Table 3** Safety of the 367 endoscopic full-thickness resection (eFTR) procedures.

<table>
<thead>
<tr>
<th>Adverse events, n (%)</th>
<th>34 (9.3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild adverse events¹</td>
<td></td>
</tr>
<tr>
<td>· Bleeding</td>
<td>8 (2.2)</td>
</tr>
<tr>
<td>· Perforation (1 immediate / 1 delayed)</td>
<td>2 (0.5)</td>
</tr>
<tr>
<td>· Post-polypectomy syndrome</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>· Urinary retention</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>· Abdominal pain</td>
<td>2 (0.5)</td>
</tr>
<tr>
<td>· Periappendiceal abscess</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>· Collapse</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Moderate adverse events²</td>
<td></td>
</tr>
<tr>
<td>· Bleeding</td>
<td>7 (1.9)</td>
</tr>
<tr>
<td>· Abdominal pain</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Severe adverse events³</td>
<td></td>
</tr>
<tr>
<td>· Perforation (2 immediate / 5 delayed)</td>
<td>7 (1.9)</td>
</tr>
<tr>
<td>· Appendicitis</td>
<td>3 (0.8)</td>
</tr>
<tr>
<td>Indication for surgery, n (%)</td>
<td>65 (17.7)</td>
</tr>
<tr>
<td>· No eFTR performed</td>
<td>13 (3.5)</td>
</tr>
<tr>
<td>· R1/Rx eFTR resection</td>
<td>11 (3.0)</td>
</tr>
<tr>
<td>· One or more high risk CRC features</td>
<td>18 (4.9)</td>
</tr>
<tr>
<td>· Adverse events</td>
<td>10 (2.7)</td>
</tr>
<tr>
<td>· Perforation</td>
<td>7 (7.0)</td>
</tr>
<tr>
<td>· Appendicitis</td>
<td>3 (30.0)</td>
</tr>
<tr>
<td>· No surgery due to comorbidities</td>
<td>7 (1.9)</td>
</tr>
<tr>
<td>· Other⁴</td>
<td>6 (1.6)</td>
</tr>
<tr>
<td>Median hospital stay (IQR), days</td>
<td>1.0 (1–1)</td>
</tr>
</tbody>
</table>

CRC: colorectal cancer; IQR, interquartile range.

¹ Mild: unplanned hospital admission or prolongation of hospital stay for ≤ 3 days or post-procedure medical consultation or procedure aborted (or not started) because of an adverse event.

² Moderate: unplanned hospital admission or prolongation of hospital stay for > 4–10 days or intensive care admission for 1 night or radiological intervention or transfusion or repeat endoscopy for an adverse event or unplanned anesthesia/ventilation support, i.e. endotracheal intubation during conscious sedation.

³ Severe: unplanned hospital admission or prolongation of hospital stay for > 10 days or intensive care admission for > 1 night or surgery for an adverse event or permanent disability [18].

⁴ Surgical resection was due to a synchronous CRC (n = 2), another polyp that could not be endoscopically resected (n = 1), preference for a surgical resection (n = 1), and the presence of mucin fields (n = 1). One patient participated in a trial and also received chemotherapy.
lengae posed by submucosal fibrosis, which makes safe en bloc EMR or ESD difficult.

Although the learning curve for eFTR is acknowledged to be shorter than for ESD, eFTR remains a challenging procedure with several limitations [3]. At present, a consensus on appropriate patient selection for eFTR is lacking. The main limitation for colorectal eFTR is the limited lesion size that can be treated. The FTRD system accommodates lesions with a maximum diameter of 30 mm [16]. In contrast to Schmidt and colleagues, we did not find a significant difference in the R0 resection rate between lesions >20 mm (72.7 %) vs. lesions ≤20 mm (78.3 %; P = 0.71) [3, 11]. However, our subgroup of lesions larger >20 mm is relatively small and might have biased our results. Considering these results together with an average size of 23 mm for the resected specimen, we recommend lesions with a maximum estimated diameter of 20 mm appropriate for eFTR.

Further technical limitations of the device are the impaired visibility and tip flexibility due to the long cap. Using a “dummy” cap (prOVE cap; Ovesco Endoscopy AG) when it is suspected that introduction will be difficult or there is doubt about wall mobility could help to optimize patient selection. In our study, we report a relatively high rate of device malfunction (9.2 %). However, in the majority of cases (84 %), the procedure could be completed with clinical success. For this matter, we believe this rate of device malfunction is acceptable.

The most frequent indication for eFTR in our cohort was T1 CRC (n = 221; 60.2 %) [3]. Although literature is scarce, our R0 resection rate for T1 CRCs of 88.2 % compares favorably with previous studies [1, 3].

In the group of patients with primary eFTR for T1 CRC, the R0 resection rate was 77.9 % in our study. The retrospective study of Kuellmer and colleagues reported a lower R0 resection rate of 60.9 % [1]. This difference in R0 resection rate could be explained by differences in the average size of the resected lesion, 20 mm in the German study vs. 14 mm in ours. Besides, in contrast to the prospective inclusion of lesions suspicious for T1 CRC in our study, Kuellmer and colleagues included mainly non-lifting lesions that were initially classified as benign but histopathologically confirmed complete scar excision is lacking, and therefore in clinical practice one is relying on the macroscopic completeness of scar resection. However, long-term outcomes are lacking and further data are therefore warranted.

The second most prevalent indication in our cohort was “difficult polyps,” consisting of non-lifting polyps or polyps that were involving difficult locations. Overall, the R0 resection rate for this subgroup was 70.5 %, which was lower compared with the previously reported R0 rate of 77.7 % in the study by Schmidt et al. [3]. However, we included mainly recurrent lesions after previously incomplete resections. As mentioned, submucosal scarring can limit adequate tissue mobilization into the cap [6, 11]. From our experience, mobilization of recurrent lesions after previous EMR can be challenging. In 14 patients (3.9 %), eFTR could not be performed because the lesion could not be mobilized into the cap. Of these, 12 were scarred lesions previously treated with EMR. In certain cases, a dummy cap may help to improve patient selection.

Adverse events occurred in 9.3 %, with 2.7 % being classified as severe. This severe adverse event rate requiring emergency surgery is comparable with previous studies (Schmidt et al., 2.2 %; Kuellmer et al., 3.8 %) [1, 3]. Nevertheless, future efforts will hopefully further decrease complication rates. The most feared complication is a delayed perforation, which occurred in 1.6 % of procedures and predominantly in the left-sided colon. Owing to partial wall excision, a relative stenosis can occur at the level of the clip. As fecal content is more solid in the distal colon, high pressures at the level of the clip could contribute to tissue disintegration or rupture. None of the three patients with delayed sigmoid perforation in our registry received post-procedural stool softeners. Although debatable, we believe prescribing post-procedural laxatives might reduce the delayed perforation risk in left-sided lesions.

Another cause of severe adverse event was appendicitis, occurring in 20.0 % of procedures for appendiceal lesions without previous appendectomy. Closure of the remaining appendix by the clip carries a risk of acute appendicitis, most likely from retained mucus [13]. Schmidt and colleagues reported a lower secondary appendicitis rate of 8.8 % [3]. There is no clear explanation for this discrepancy, although both are based on small subgroups. Larger cohorts with adequate follow-up are required to elucidate the position of eFTR in appendiceal lesions. In the meantime, patients should be well informed about the risk of secondary appendicitis.

Our study has several limitations that should be addressed. First, because this study is based on registry data, we cannot exclude potential selection bias and must rely on accurate data recording in all 20 participating centers. Second, follow-up data were not complete because not all surveillance colonoscopies had been performed or recorded yet. However, this registry...
started in a strong and transparent collaboration of 20 academic and non-academic centers and represents a good overview of eFTR for colorectal lesions in current clinical practice.

In conclusion, eFTR is an exciting innovative resection technique that is clinically feasible and safe for complex colorectal lesions (≤20 mm), with the potential to obviate the need for surgical resection. Further efficacy studies on eFTR as a primary and secondary treatment option for T1 CRC are needed, focusing on both the short- and long-term oncological results.

Acknowledgments

We thank all participating endoscopists of the eFTR working group for their efforts and cooperation and we want to thank dr. Lianne Koens, pathologist at Amsterdam UMC for providing the histology images.

A single unrestricted grant from Ovesco Endoscopy AG was received for database costs. Ovesco Endoscopy AG was not involved in the design, collection, analysis, or interpretation of our data. No other funding was received. No endoscopic equipment was donated by the manufacturer.

Competing interests

P. Fockens receives personal fees from Cook, Ethicon, and Olympus, and research support from Boston Scientific outside the submitted work. E. Dekker has endoscopic equipment on loan from FujiFilm, and has received a research grant from FujiFilm, consultancy fees from FujiFilm, Olympus, Tillotts, GI Supply, and CIP-FAP, and speaker’s fees from Olympus, Roche, and GI Supply. B. Bastiaansen has received speaker’s fees from Olympus, Tillotts Pharma AG, and Ovesco Endoscopy AG. The remaining authors declare that they have no conflict of interest.

Clinical trial

Trial Registration: Dutch Trial Register | Registration number (trial ID): NTR6292 | Type of study: Prospective study

References


